SCHEMBL2902900

SCHEMBL2902900

O=C(O)c1cccnc1I

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.63
TDP1 Q9NUW8 1/20 0.63
ALDH1A1 P00352 6/20 0.61
L3MBTL1 Q9Y468 3/20 0.61
ALOX15 P16050 2/20 0.61
CYP3A4 P08684 1/20 0.61
MAPT P10636 1/20 0.61
TSHR P16473 1/20 0.61
BLM P54132 1/20 0.61
AGER Q15109 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
SMN1; SMN2 Q16637 3/20 0.59
NAPRT Q6XQN6 2/20 0.59
LMNA P02545 2/20 0.59
DHODH Q02127 3/20 0.50
MYC P01106 1/20 0.49
ALOX12 P18054 1/20 0.46
CYP2C9 P11712 1/20 0.46
KDM6B O15054 1/20 0.46
KDM6A O15550 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30863406 1.00 KDM4E (0.63) KDM4ETDP1ALDH1A1L3MBTL1ALOX15
Nitrous Acid SCHEMBL27941916 0.92 ALDH1A1 (0.58) KDM4ETDP1ALDH1A1L3MBTL1ALOX15
SCHEMBL12469484 0.81 PARP1 (0.56) KDM4ETDP1ALDH1A1L3MBTL1ALOX15
SCHEMBL16414377 0.81 KDM4E (0.45) KDM4ETDP1ALDH1A1L3MBTL1ALOX15
SCHEMBL1807370 0.80 TDP1 (0.55) KDM4ETDP1ALDH1A1L3MBTL1ALOX15
SCHEMBL270419 0.77 KDM4E (1.00) KDM4ETDP1ALDH1A1L3MBTL1ALOX15
SCHEMBL15850545 0.77 KDM4E (0.77) KDM4ETDP1ALDH1A1L3MBTL1ALOX15
SCHEMBL21048718 0.76 PTPN1 (0.44) KDM4ETDP1ALDH1A1L3MBTL1ALOX15
SCHEMBL22258205 0.76 POLB (0.69) TDP1ALDH1A1L3MBTL1CYP3A4MAPT
SCHEMBL6032802 0.76 TSHR (0.59) KDM4EALDH1A1L3MBTL1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115521249-B 2- [4- (1-Oxo alkyl) phenoxy ] -3-picolinic acid, preparation method and application thereof 沈阳兴齐眼药股份有限公司 2025-03-11 CN claimed
US-20240343738-A1 Method for preparing pranoprofen and composition comprising pranoprofen and impurity SHENYANG XINGQI PHARMACEUTICAL CO., LTD. (CN) 2024-10-17 US claimed
EP-4361155-A1 METHOD FOR PREPARING PRANOPROFEN AND COMPOSITION CONTAINING PRANOPROFEN AND IMPURITY Shenyang Xingqi Pharmaceutical Co., Ltd. (CN) 2024-05-01 EP claimed
CN-114685365-B Synthesis method of diflufenican 青岛润农化工有限公司 2023-06-30 CN claimed
WO-2022267945-A1 METHOD FOR PREPARING PRANOPROFEN AND COMPOSITION CONTAINING PRANOPROFEN AND IMPURITY 沈阳兴齐眼药股份有限公司 2022-12-29 WO claimed
CN-115521249-A 2- [4- (1-oxoalkyl) phenoxy ] -3-picolinic acid, preparation method and application thereof 沈阳兴齐眼药股份有限公司 2022-12-27 CN claimed
CN-114685365-A Synthetic method of diflufenican 青岛润农化工有限公司 2022-07-01 CN claimed
CN-115521249-B 2- [4- (1-Oxo alkyl) phenoxy ] -3-picolinic acid, preparation method and application thereof 沈阳兴齐眼药股份有限公司 2025-03-11 CN disclosed
CN-115521250-B 2- (10-Hydroxy-9-oxa-1-aza-6-yl) propionate compound, and preparation method and application thereof 沈阳兴齐眼药股份有限公司 2024-12-27 CN disclosed
CN-115521251-B Pranoprofen intermediate compound, preparation method and application thereof 沈阳兴齐眼药股份有限公司 2024-12-27 CN disclosed
US-20240343738-A1 Method for preparing pranoprofen and composition comprising pranoprofen and impurity SHENYANG XINGQI PHARMACEUTICAL CO., LTD. (CN) 2024-10-17 US disclosed
EP-4361155-A1 METHOD FOR PREPARING PRANOPROFEN AND COMPOSITION CONTAINING PRANOPROFEN AND IMPURITY Shenyang Xingqi Pharmaceutical Co., Ltd. (CN) 2024-05-01 EP disclosed
CN-115521320-B Method for preparing pranoprofen 沈阳兴齐眼药股份有限公司 2023-09-05 CN disclosed
EP-2647620-A1 STABLE SYNTHETIC INTERMEDIATE AND METHOD FOR MANUFACTURING SAME Kyorin Pharmaceutical Co., Ltd. (JP) 2013-10-09 EP disclosed
WO-2010147776-A1 SUBSTITUTED -1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES MERCK SHARP & DOHME CORP. (US) 2010-12-23 WO disclosed
EP-2240178-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-10-20 EP disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 WO disclosed
EP-1086080-B1 DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2004-08-25 EP disclosed
EP-1086080-A1 DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS Galderma Research & Development, S.N.C. (FR) 2001-03-28 EP disclosed
WO-1999065872-A1 DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 1999-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343738-A1 Method for preparing pranoprofen and composition comprising pranoprofen and impurity CYP3A5, CYP3A43, CYP4A11 KDM4E 3123/4885TDP1 991/4885ALDH1A1 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.